-+ 0.00%
-+ 0.00%
-+ 0.00%

Kura Oncology forms Caspian Therapeutics, which raises USD 50 million in Series A financing

PUBT·09/09/2026 11:12:45
Listen to the news
Kura Oncology forms Caspian Therapeutics, which raises USD 50 million in Series A financing
  • Kura Oncology formed Caspian Therapeutics to develop next-generation menin inhibitors for diabetes and other cardiometabolic diseases.
  • Caspian raised USD 50 million in a Series A private financing on Sept. 8, 2026; Kura invested USD 4.3 million.
  • Kura contributed rights to KO-7246 and related intellectual property to Caspian for common stock, retaining about 49.2% ownership.
  • Deal includes cross-licenses, giving Caspian paid-up rights to certain ziftomenib patents for cardiometabolic use.
  • Kura will provide R&D and administrative services to Caspian under an intercompany services agreement with annual renewals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-385881), on September 09, 2026, and is solely responsible for the information contained therein.